HOME >> MEDICINE >> NEWS
Advance reported in search for skin cancer treatment

In a search for skin cancer treatments, chemists at the University of Notre Dame have constructed a computer model of the chemical structure of an enzyme that many organisms use to repair DNA damaged by ultraviolet light. Their findings are reported in the June 9 issue of the Journal of the American Chemical Society and are now on the journal's website at http://pubs.acs.org/journals/jacsat/index.html.

According to Olaf Wiest, assistant professor of chemistry and biochemistry and principal investigator, the ultimate goal of the research is to produce an artificial enzyme for human use that could repair DNA damaged by ultraviolet light in humans. Such damage leads to certain types of skin cancer, which have reached almost endemic proportions. Skin cancer is now the most common form of cancer in the United States, with an estimated 1.4 million cases diagnosed annually. According to Wiest, the number of skin cancer patients has risen steadily over the past 20 years.

The computer model provides atomic details of the binding interactions of damaged DNA and DNA photolyase, the repair enzyme of the bacterium Escherichia coli. According to Wiest, the model provides new insights into which parts of the enzyme are important for electron transfer that repairs the damage.

DNA photolyase and other mechanisms are used by many organisms, suc h as yeast and algae -- but not humans -- to protect against damage by ultraviolet light. By understanding how the protection mechanisms in these organisms work, scientists may be able to develop ways to protect humans from these types of skin cancer, Wiest says.

"To the best of our knowledge, our model is the first to explain all the pertinent experimental data -- binding and alkylation studies, spectroscopic data, rate constants and mutagenesis results -- in a consistent fashion," Wiest says. "It is
'"/>

Contact: Olaf Wiest
wiest.1@nd.edu
219-631-5876
University of Notre Dame
3-Jun-1999


Page: 1 2

Related medicine news :

1. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
2. Advances in plasma physics at Annual APS Meeting
3. Advances in plasma physics at Annual APS Meeting
4. Advanced, precise radiation may boost limb-sparing therapy for sarcoma
5. Advances in understanding brain circuits responsible for tics in Tourettes shed light on disorder
6. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
7. Advances emerging in hepatitis management
8. Advanced small-cell lung cancer patients
9. Advances in prevention and treatment research hold promise for pipeline
10. Advances in MRI imaging may lead to new standards for faster diagnosis of multiple sclerosis
11. Peanut Allergy: Major Advances in Treatment and Education

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Advance reported search for skin cancer treatment

(Date:5/24/2013)... 2013 The Dictation Source recently added ... clients. As a result of its National marketing efforts, ... 20 states around the nation. , Since 1991, The ... to the healthcare industry . Dictation Source is owned ... years of clinical work experience to provide the solutions ...
(Date:5/24/2013)... May 24, 2013 Based in ... a leading nationwide sales, installation and service provider ... and commercial applications. The company’s core products include ... lifts for mobility devices, pool lifts, turning automotive ... operates over 30 locations, primarily through its franchise ...
(Date:5/24/2013)... in five parents think they have little control over ... drug use, a new U.S. government survey finds. ... and Mental Health Services Administration (SAMHSA), since new research ... influential forces helping to shape their child,s views on ... that parents can make an enormous difference in influencing ...
(Date:5/24/2013)... The SunglassFIX Photo Contest lets ... while learning how to make their sunglasses, and ... only need to upload pictures of themselves, friends ... Sunglass Fix on Facebook in order to enter. ... lens replacement online store . , ...
(Date:5/24/2013)... A new investigational device - the Helio System (TF-FA) ... Transcatheter Heart Valve was successfully deployed in all four ... use in high-risk aortic insufficiency reported at EuroPCR 2013. ... to help stabilise the SAPIEN XT valve for patients ... are captured between the transcatheter heart valve and the ...
Breaking Medicine News(10 mins):Health News:The Dictation Source Signs Two National Hospital Chains 2Health News:The Dictation Source Signs Two National Hospital Chains 3Health News:Cortec Closes Equity Transaction with 101 Mobility 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win 2Health News:Feasibility trial reports deployment of new device for TAVI in aortic insufficiency 2
(Date:5/24/2013)... , May 24, 2013 China Biologic ... a leading fully integrated plasma-based biopharmaceutical company in ... has recently learned from a public announcement issued by ... public company listed on Shenzhen Stock Exchange, that on ... ("Ms. Chan"), one of the shareholders of ...
(Date:5/24/2013)... , May 24, 2013 In accordance with ... and Rule 14e-1 of the United States Exchange Act, Echo ... original offer for Elan Corporation (NYSE: ELN). Background ... ("Royalty Pharma") made an offer for the entire of the ... plc ("Elan") (the "Original Offer").  On 20 ...
(Date:5/24/2013)... LONDON , May 24, 2013 ... non-invasive administration for systemic delivery of therapeutic agents has ... the inhalation drug delivery showing significant promise. The crucial ... of a delivery device play a major role in ... been made in the development of new formulation techniques ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
Cached News: